Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.

Michael M MalatyTahrima KayesAnjalee T AmarasekeraMatthew KodsiC Raina MacIntyreTimothy C Tan

Published in: European journal of clinical investigation (2020)

Patients with SARS-CoV-2 are at an increased risk of arrhythmias. Drug therapy is pro-arrhythmogenic and may result in TdP and SCD in these patients. Risk assessment and regular QTc monitoring are imperative for safety during the treatment course. Further studies are needed to guide future decision-making.

Keyphrases

sars cov
risk assessment
decision making
end stage renal disease
ejection fraction
newly diagnosed
risk factors
prognostic factors
stem cells
peritoneal dialysis
congenital heart disease
heavy metals
current status
anti inflammatory
adverse drug
smoking cessation